BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs

BioRestorative Therapies, Inc.

Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.
Gross proceeds ~$5.0M net of ~7% placement agent fee and expenses.
Proceeds to fund BRTX-100 Phase 2 trial, ThermoStem R&D, biocosmeceuticals platform, and working capital.
Rodman & Renshaw acted as exclusive placement agent; 90-day lockup on new equity issuances.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioRestorative Therapies, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2026-02-11).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2026-02-11

Exact text from the filing

On February 11, 2026, BioRestorative Therapies, Inc. (the “Company”) commenced a public offering (the “Offering”) of an aggregate of (a) 12,560,715 units (the “Common Units”), consisting of (i) 12,560,715 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) five-year warrants to purchase up to 12,560,715 shares of Common Stock (the “Common Stock Warrants”), at an offering price of $0.35 per Common Unit, and (b) 1,725,000 units (the “Pre-Funded Units”), consisting of (i) pre-funded warrants to purchase up to 1,725,000 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) five-year warrants to purchase up to 1,725,000 shares of Common Stock, at an offering price of $0.3499 per Pre-Funded Unit.

View on SEC.gov

303 material agreements filed in the last 30 days. Browse all material agreements →

BioRestorative Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-006837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.